Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Human liver using 1:200 dilution of anti-Osteoprotegerin/TNFRSF11B antibody (clone 98A1071). The staining was developed with HRP labeled secondary antibody and DAB reagent, and nuclei of cells were counter-stained with hematoxylin. This Osteoprotegerin antibody generated a diffused but weak cytoplasmic staining with a very specific and strong punctate signal at the periphery of the cells.

Western Blot: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Total protein from human MG63 and Daudi cell lines was separated on a 7.5% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 1.0 ug/ml anti-Osteoprotegerin in blocking buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.

Immunocytochemistry/Immunofluorescence: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - MG-63 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X PBS + 0.05% Triton X-100. The cells were incubated with anti-Osteoprotegerin (98A1071) at 5 ug/ml overnight at 4C and detected with an anti-mouse DyLight 488 (Green) at a 1:500 dilution. Actin was detected with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.

Flow Cytometry: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Intracellular staining of 10^6 HeLa cells using 0.2 ug of OPG antibody, 0.5 ul of PE secondary.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Human breast tissue stained with OPG antibody (5 ug/ml), peroxidase-conjugate and DAB chromogen.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Staining of human liver. Tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.

Immunohistochemistry-Paraffin: Osteoprotegerin/TNFRSF11B Antibody (98A1071) [NB100-56505] - Staining of human heart tissue after heat-induced antigen retrieval. Antibody concentration 5 ug/ml.

• Reactivity: Hu, Mu, Rt, Rb
• Applications: WB, ELISA, Flow, ICC/IF, IHC, IP, CyTOF-ready
• Clone: 98A1071
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1.0 mg/ml

Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free Summary

• Immunogen: A peptide corresponding to the amino acids 20-37 TQETFPPKYLHYDEETSH of human Osteoprotegerin was used as immunogen for this antibody.
• Specificity: The Osteoprotegerin antibody, clone 98A1071, detects all forms of Osteoprotegerin including monomeric, dimeric and Osteoprotegerin bound to RANKL (Vandooren, 2008) as well as Osteoprotegerin bound to TRAIL (Sandra, 2006).
• Isotype: IgG1 Kappa
• Clonality: Monoclonal
• Host: Mouse
• Gene: TNFRSF11B
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • CyTOF-ready
  • ELISA reported in scientific literature (PMID 15935726)
  • Flow Cytometry 0.2-1 ug/1 million cells
  • Immunocytochemistry/Immunofluorescence 1:20-1:1000. Use reported in scientific literature (Sandra (2006))
  • Immunohistochemistry 1:100-1:1000
  • Immunohistochemistry-Frozen 1:20-1:1000. Use reported in scientific literature (Boumans (2012))
  • Immunohistochemistry-Paraffin 1:100-1:1000
  • Immunoprecipitation 1:20-1:1000. Use reported in scientific literature (Sandra (2006))
  • Western Blot 1 ug/ml
• Application Notes: This antibody is CyTOF ready.

Reactivity Notes

Rabbit reactivity reported in scientific literature (PMID: 31658685).

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS
• Preservative: 0.05% Sodium Azide
• Concentration: 1.0 mg/ml
• Purity: Protein G purified

Alternate Names for Osteoprotegerin/TNFRSF11B Antibody (98A1071) - BSA Free

• OCIF
• OCIFMGC29565
• OPG
• OPGtumor necrosis factor receptor superfamily member 11B
• Osteoclastogenesis inhibitory factor
• Osteoprotegerin
• TNFRSF11B
• TR1
• tumor necrosis factor receptor superfamily, member 11b

Background

Osteoprotegerin (OPG) is a secretory glycoprotein belonging to TNF receptor (TNFR) superfamily. As the name implies, it protects bone. Unlike other TNFRs it lacks a transmembrane domain and lacks any apparent cell associated signals. OPG consists of 401 amino acid with molecular mass of approximately 55 kD as a monomer and 110 kD as a disulfide-linked dimer. High levels of OPG mRNA has been detected in lung, heart, kidney, and placenta1. Recombinant OPG blocks osteoclastogenesis in vitro and increases bone density in vivo. Targeted deletion of OPG in mice results in severe early-onset of osteoporosity. These mice also exhibit increase in vascular calcification in the aorta and renal arteries suggesting that it may also play a role in degenerative arterial disease.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Osteoprotegerin/TNFRSF11B Antibody (NB100-56505)(38)

Publications using NB100-56505

• Kumar K, Datta K, Fornace A, Suman S Total body proton and heavy-ion irradiation causes cellular senescence and promotes pro-osteoclastogenic activity in mouse bone marrow Heliyon 2022-01-01 [PMID: 35028468] (IHC-P, Mouse)
• Boumans MJ, Thurlings RM, Yeo L et al. Rituximab abrogates joint destruction in rheumatoid arthritis by inhibiting osteoclastogenesis. Ann Rheum Dis. 2012-01-01 [PMID: 22072013]
• Sengun MC, Gunpinar S Effects of systemic hydroxytyrosol application in experimental periodontitis of rats International Journal of Plant Based PHARMACEUTICALS 2022-01-01 (IF/IHC, Rat)
• Lysitska A, Galanis N, Skandalos I Et al. Histology and Immunohistochemistry of Radial Arteries Are Suggestive of an Interaction between Calcification and Early Atherosclerotic Lesions in Chronic Kidney Disease Medicina 2021-10-24 [PMID: 34833374] (IHC-P, Human)
• Zhang Q, Chen T, Zhang Y, et al. MiR-30c-5p regulates adventitial progenitor cells differentiation to vascular smooth muscle cells through targeting OPG Stem Cell Research & Therapy 2021-12-01 [PMID: 33468212] (WB)
• Jiang Y, Li J, Li G et al. Osteoprotegerin interacts with syndecan-1 to promote human endometrial stromal decidualization by decreasing Akt phosphorylation Hum Reprod 2020-11-01 [PMID: 33047116]
• Bayer Alinca S, Saglam E, Zengin Celik T et al. Is low level laser therapy or ozone therapy more effective for bone healing? Understanding the mechanisms of HIF-1alpha, RANKL and OPG Biotech Histochem 2020-04-15 [PMID: 32292090]
• Lee YC, Chan YH, Hsieh SC et al. Comparing the Osteogenic Potentials and Bone Regeneration Capacities of Bone Marrow and Dental Pulp Mesenchymal Stem Cells in a Rabbit Calvarial Bone Defect Model Int J Mol Sci 2019-10-10 [PMID: 31658685] (IF/IHC, Rabbit)
• Wang X, Cao Y, Liu Z et al. Alveolar Bone Density Reduction in Rats Caused by Unilateral Nasal Obstruction Balkan Med J 2019-10-28 [PMID: 31290639] (WB, Rat)
• Gegen T, Zhu Y, Sun QHou B Role of interleukin-33 in the clinical pathogenesis of chronic apical periodontitis J. Int. Med. Res. 2019-06-20 [PMID: 31218936] (IF/IHC, Human)
• Li , Wang C, Li Z et al. Nano-sized Al2O3 particle-induced autophagy reduces osteolysis in aseptic loosening of total hip arthroplasty by negative feedback regulation of RANKL expression in fibroblasts Cell Death Dis 2018-08-12 [PMID: 30082761] (WB, IF/IHC, Human)
• El Kholy K, Freire M, Chen T, Van Dyke TE. Resolvin E1 Promotes Bone Preservation Under Inflammatory Conditions Front Immunol 2018-06-12 [PMID: 29946319] (Mouse)
• Nozawa S, Inubushi T, Irie F, Takigami I. Osteoblastic heparan sulfate regulates osteoprotegerin function and bone mass. JCI Insight. 2018-02-08 [PMID: 29415886] (ICC/IF, Human)
• Scimeca M, Salustri A, Bonanno E et al. Impairment of PTX3 expression in osteoblasts: a key element for osteoporosis. Cell Death Dis. 2017-10-12 [PMID: 29022895] (Human)
• Stanislawowski M, Wisniewski P, Guzek M et al. Influence of receptor activator of nuclear factor kappa B ligand, osteoprotegerin and interleukin-33 on bone metabolism in patients with long-standing ulcerative colitis. J Crohns Colitis. 2014-01-15 [PMID: 24439762] (IHC-Fr, Human)
  
  Details:
  Colonic mucosa biopsies, Fig 7C
• Larson SR, Zhang X, Dumpit R et al. Characterization of osteoblastic and osteolytic proteins in prostate cancer bone metastases. Prostate. 2013-06-01 [PMID: 23334979]
• Witasp Anna, Carrero Juan J, Hammarqvist Folke et al. Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease. Eur J Clin Invest. 2011-05-01 [PMID: 21128937] (Human)
• Tomlins Christine, Storey Alan. Cutaneous HPV5 E6 causes increased expression of Osteoprotegerin and Interleukin 6 which contribute to evasion of UV-induced apoptosis. Carcinogenesis. 2010-12-01 [PMID: 20884685] (WB)
• Pohjolainen V, Taskinen P, Soini Y et al. Noncollagenous bone matrix proteins as a part of calcific aortic valve disease regulation. Hum Pathol. 2008-11-01 [PMID: 18701137]
• Vandooren B, Cantaert T, Noordenbos T et al. The abundant synovial expression of the RANK/RANKL/Osteoprotegerin system in peripheral spondylarthritis is partially disconnected from inflammation. Arthritis Rheum. 2008-03-01 [PMID: 18311801]
• Waterman EA, Cross NA, Lippitt JM et al. The antibody MAB8051 directed against osteoprotegerin detects carbonic anhydrase II: implications for association studies with human cancers. Int J Cancer. 2007-11-01 [PMID: 17631639]
• Pettit AR, Walsh NC, Manning C et al. RANKL protein is expressed at the pannus-bone interface at sites of articular bone erosion in rheumatoid arthritis. Rheumatology (Oxford). 2006-09-01 [PMID: 16490750]
• Sandra F, Hendarmin L, Nakamura S. Osteoprotegerin (OPG) binds with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL): suppression of TRAIL-induced apoptosis in ameloblastomas. Oral Oncol. 2006-04-01 [PMID: 16413220]
• Pettersen Ingvild, Bakkelund Wenche, Smedsrod Bard, Sveinbjornsson Baldur. Osteoprotegerin is expressed in colon carcinoma cells. Anticancer Res. 2005-11-01 [PMID: 16309167]
• Gaudio A, Lasco A, Morabito N et al. Hepatic osteodystrophy: does the osteoprotegerin/receptor activator of nuclear factor-kB ligand system play a role? J Endocrinol Invest. 2005-09-01 [PMID: 16277162] (IHC-P)
• Moschen AR, Kaser A, Stadlmann S et al. The RANKL/OPG system and bone mineral density in patients with chronic liver disease. J Hepatol. 2005-12-01 [PMID: 16143421]
• Moran CS, McCann M, Karan M et al. Association of osteoprotegerin with human abdominal aortic aneurysm progression. Circulation. 2005-06-14 [PMID: 15939823] (IHC-P, WB)
  
  Details:
  IHC (p): healthy and aneurysmal aortic biopsies, Fig 2A,B. WB: aortic biopsies (Fig 2C, D) and recombinant OPG (Fig 2D). OPG was detected at 55 kDa. An ~75 kDa band was also detected on one of the samples. OPG quantification was performed by comparison of
• Sandra F, Hendarmin L, Kukita T et al. Ameloblastoma induces osteoclastogenesis: a possible role of ameloblastoma in expanding in the bone. Oral Oncol. 2005-07-01 [PMID: 15935726] (ELISA, Human)
  
  Details:
  Ameloblastoma tumor tissue and AM-1 cells: 1. OPG (IMG-103A), ELISA (detection): Results described.
• Moschen AR, Kaser A, Enrich B et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut. 2005-04-01 [PMID: 15753532] (IHC-P)
• Vidal K, Serrant P, Schlosser B et al. Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. Am J Physiol Gastrointest Liver Physiol. 2004-10-01 [PMID: 15521102]
• Vidal K, van den Broek P, Lorget F et al. Osteoprotegerin in human milk: a potential role in the regulation of bone metabolism and immune development. Pediatr Res. 2004-06-01 [PMID: 15155868]
• Golledge J, McCann M, Mangan S, Lam A et al. Osteoprotegerin and osteopontin are expressed at high concentrations within symptomatic carotid atherosclerosis. Stroke. 2004-07-01 [PMID: 15143295]
• Standal T, Seidel C, Hjertner O et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. Blood. 2002-10-15 [PMID: 12351414] (IHC-P)
• Komuro H, Olee T, Kuhn K et al. The osteoprotegerin/receptor activator of nuclear factor kappaB/receptor activator of nuclear factor kappaB ligand system in cartilage. Arthritis Rheum. 2001-12-01 [PMID: 11762937]
• Fiumara P, Snell V, Li Y et al. Functional expression of receptor activator of nuclear factor kappaB in Hodgkin disease cell lines. Blood. 2001-11-01 [PMID: 11675352]
• Pearse RN, Sordillo EM, Yaccoby S et al. Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. Proc Natl Acad Sci U S A. 2001-09-25 [PMID: 11562486]
  
  Details:
  Antibodies cited [IHC (paraffin)], Figs 1 and 4 (human plasmocytoma and decalified bone marrow): 1. OPG (IMG-103) 2. Trance/RankL/OPGL/ODF (IMG-133).
• Saika M, Inoue D, Kido S, Matsumoto T. 17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha. Endocrinology. 2001-06-01 [PMID: 11356664]
• Kobayashi Y, Hashimoto F, Miyamoto H et al. Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. J Bone Miner Res. 2000-10-01 [PMID: 11028444] (Rat)

FAQs for Osteoprotegerin/TNFRSF11B Antibody (NB100-56505). (Showing 1 - 1 of 1 FAQs).

1. Are the following monoclonals purified from ascites or from tissue culture supernatant?NB100-56541, NB100-56705, NB600-1298, NB100-56534, NB100-56505, NBP2-24873, NB600-1107, NBP2-24917, NB100-56524, NB100-56712
   • These antibodies are all purified from tissue culture supernatant.

Bioinformatics

• Gene Symbol: TNFRSF11B
• Entrez:
  • 690(Human)
• Uniprot:
  • O00300()